anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Among 136 patients assessed within 12 hours for entry into the study, 109 (69 males) accepted to participate, gave an informed consent and were randomly assigned either to receive every 6 hours the nebulized 0.9% saline (NS) (group I) or the 3% HS (group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids). Patients were randomized to receive different saline treatments using a computer-based randomization program. Study solutions, prepared by the local hospital pharmacy, were blinded to participants and investigators. Each treatment was delivered by a nebulizer with continuous flow of oxygen at 6 L/min through a tight-fitting facemask.

The main study endpoints were the length of stay (LOS) in hospital and the clinical response. LOS in hospital was defined as the time between study entry (within 12 hours of admission to the hospital) and the time at which the infant was discharged on the basis of the clinical grounds by the attending physician. Clinical response was determined using daily CSS evaluation; furthermore, the CSS was evaluated every day before and 30 minutes after nebulisation.
Currently, chimeric antigen receptor modified T (CAR-T) cell therapy has achieved a series of achievements in hematological malignancies, however, it still has to face plenty of obstacles in more bulky solid tumors, such as absence of tumor specific antigens, complex immunosuppressive tumor microenvironment, and tumor heterogeneity, which may taken together to restrict the efficacy of CAR-T cells in eliminating solid tumors. Previous studies found that intratumoral hypoxic microenvironment facilitated the development and metastasis of tumor cells. Meanwhile, it was difficult for cytotoxic T cells including CAR-T cells to survive and expand in such a hypoxic microenvironment.

In this study, investigators developed a novel hypoxia-stimulated CAR expression system (HypoSti.CAR) that could enable CAR-T cell effectively expand and survive in hypoxic tumor microenvironment,which has been demonstrated in animal models. Based on the preclinical data, investigators will further conduct this clinical trial in order to test the potential of this novel system targeting HER2 antigen in vivo. In dose escalation period, at least 9 eligible patients will be enrolled and receive 5 doses of HypoSti.CAR-HER2 T cell therapy (1 × 10\^6 cells/kg, 3 × 10\^6 cells/kg, 6 × 10\^6 cells/kg,1 × 10\^7 cells/kg, 1.5 × 10\^7 cells/kg) according to the "3+3" principle. In dose expansion period, additional 10 to 21 patients will be enrolled to receive HypoSti.CAR-HER2 T cell therapy at dose of recommended phase 2 dose (RP2D), which is determined by data from dose escalation period, including occurrence of dose limiting toxicities (DLT), pharmacokinetics/pharmacodynamics, efficacy and other parameters, to furtherly evaluate the safety and efficacy profiles of HypoSti.CAR-HER2 T cell therapy.
The Dutch treatment guidelines recommend trauma-focused treatment (TFT) for PTSD. In TFT, patients are exposed to trauma reminders that they typically avoid, until their emotional reactions decline. This treatment has been found very effective for some patients but there is much room for improvement, particularly in PTSD related to childhood abuse (CA-PTSD). Symptom exacerbation, non-attendance and dropout rates of up to 40% have been observed in patients with CA-PTSD.

Two alternative treatments have been proposed. Firstly, TFT may be preceded by emotion regulation and interpersonal skills training. This is called phase-based treatment (PBT). The rationale is that patients with CA-PTSD have affect regulation and interpersonal problems that interfere with effective delivery of TFT. These problems are rooted in the detrimental developmental effects of abuse (often by an attachment figure). PBT indeed resulted in more favorable outcomes and fewer dropouts. In international guidelines, PBT was recently recommended as treatment of choice for patients with CA-PTSD and comorbidity.

Another innovative treatment is intensive TFT (i-TFT), which means delivering TFT in 4 instead of 16 weeks. The condensed format enhances learning and prevents the buildup of anticipatory anxiety, which in turn affects the patients' motivation. Patients with CA-PTSD are also characterized by high psychosocial stressors, leading to problems with treatment attendance and compliance. The condensed format may improve motivation, attendance and compliance. I-TFT was recently tested in a case series in patients with CA-PTSD and in a randomized controlled trial (RCT) with patients with adulthood-related PTSD. Both studies had very low dropout rates (0-3%) and fast recovery.

The aim of the current study is to investigate the (cost)effectiveness of two innovative forms of trauma-focused therapy for patients with CA-PTSD: phase-based therapy (emotion regulation skills training followed bij PE) and intensive PE (i-PE). The effects will be assessed post-treatment and after a 6 and 12 months follow-up in an intention-to-treat analysis. Results will be disseminated and included in treatment guidelines. The ultimate goal is to improve quality of care and contribute to treatment innovation for this severely ill target population.
On CB CGM patients, CGM data will also be transmitted from the bedside smartphone to the Digital Dashboard. The Digital Dashboard will integrate CGM data for CB CGM's participants for presentation via two views: (1) Real-Time Management and (2) Clinical Optimization. Telemetry technicians to conduct site-based monitoring, and the Diabetes APN will conduct remote management of patients at the site from a central, Scripps Diabetes Hub, per below. (Note, as CGMs are not FDA-approved for in-hospital glucose management, CB CGM participants will also have their glucose monitored via the hospital's standard POC testing protocol described for UC).
Methods and apparatus disclosed herein relate to graphical representation of oxygenation of an organism. In various embodiments, one or more measured physiological parameters of an organism may be analyzed. Based on the analysis, a graphical user interface (GUI) may be rendered. The GUI may convey oxygenation of an organism visually as a continuous physiological flow graphical element (236) that passes through four quadrants in a cycle. In various embodiments, each quadrant includes an abscissa and an ordinate that represent a relationship between at least two of the measured physiological parameters. In various embodiments, for at least some of the four quadrants, the ordinate of one quadrant comprises the abscissa of the next quadrant of the cycle.
Sickle cell anaemia (SCA) is a multisystem disorder with massive medical, social and financial implications worldwide. It is caused by a single mutation in the β-globin gene (β6 Glu\>Val), which leads to the production of abnormal sickle haemoglobin (HbS). Africa is the major origin of the sickle (βS) mutation, which occurs on diverse genetic haplotype backgrounds. SCA has a Mendelian pattern of inheritance (βS gene homozygosity, i.e. HbSS). Although all SCA patients share the same genetic mutation, the disease exhibits wide heterogeneity in clinical expression, which can be explained by both environmental and genetic factors. The environmental factors include infections, trauma, climate (temperature and humidity) and air quality, as well as socioeconomic factors, many of which are controllable. The genetic factors, on the other hand, cannot be controlled. The best-characterized genetic factors include variants in the genes associated with foetal haemoglobin (HbF) production, co-inheritance of alpha-thalassaemia, sickle genotype, and the type of βS-globin haplotype. The role of other potential genetic modifiers is less clear, particularly with regards to sickle cell disease related organ damage (e.g., risk for stroke, haemolysis, and acute chest syndrome.

Understanding the molecular basis of clinical heterogeneity and disease severity for SCA can have direct clinical applications for prognosis via risk stratification of patients, also facilitating the use of personalized, targeted therapeutic interventions. As a turning-point in genomics, the advent of high-throughput sequencing and whole-genome analysis has made it feasible to discover hitherto unsuspected variants that could add to current understanding of genotype-phenotype relationships in SCA. The identification of modifying genetic variants might suggest new prognostic and/or therapeutic targets for investigation towards improved patient management and treatment.
OBJECTIVE: To investigate the effectiveness of linezolid and vancomycin for the treatment of nosocomial infections in children under 12 years old.
DATA SOURCES: This is a systematic review in which five randomized clinical trials about the effectiveness of linezolid and vancomycin, involving a total of 429 children with nosocomial infections, were evaluated. They were searched in scientific databases: PubMed, Bvs, and SciELO.
SUMMARY OF FINDINGS: The main nosocomial infections that affected children were bacteremia, skin, and soft tissue infections followed by nosocomial pneumonia. Most infections were caused by Gram-positive bacteria, which all studies showed infections caused by Staphylococcus aureus, with methicillin-resistant S. aureus (MRSA) and methicillin-resistant coagulase-negative staphylococci strains being isolated. Both linezolid and vancomycin showed high therapeutic efficacy against different types of nosocomial infections, ranging from 84.4% to 94% for linezolid and 76.9% to 90% for vancomycin. Patients receiving linezolid had lower rates of rash and red man syndrome compared to those receiving vancomycin. However, despite the adverse reactions, antimicrobials can be safely administered to children to treat nosocomial infections caused by resistant Gram-positive bacteria.
CONCLUSION: Both linezolid and vancomycin showed good efficacy in the treatment of bacterial infections caused by resistant Gram-positive bacteria in hospitalized children. However, linezolid stands out regarding its pharmacological safety. Importantly, to strengthen this conclusion, further clinical trials are needed to provide additional evidence.
<P>PROBLEM TO BE SOLVED: To provide a method for industrially advantageously in an easy process, producing a dentifrice which is uniformly dispersed binder or the like and is excellent in shape-retaining property and surface gloss.  <P>SOLUTION: The invention relates to the method for producing the dentifrice comprising the binder, a polishing agent, a foaming agent, a moistening agent, a perfume and water. The method comprises the steps of: preparing an aqueous solution of the moistening agent with a ratio of the moistening agent/water=85/15-40/60 (mass ratio) and then feeding the binder powder with the aqueous solution to a continuous mixing and dispersing machine to prepare the binder dispersing liquid; swelling and dissolving the binder in the binder dispersing liquid by feeding liquid material containing the binder dispersing liquid and remaining water to the mixing machine; and mixing remaining materials containing perfume, polishing agent, the foaming agent to the swelling solution of the binder. A uniform dispersion (partly swelling) without formation of undissolved lump is obtained according to the above method. The adhesion of a remaining substance to piping can be suppressed and the number of small tanks required can be reduced. An effective swelling and dissolving can be carried out and thus, a high quality dentifrice with excellent shape-retaining property and surface gloss is effectively produced.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Provided herein are methods of populating a target tissue of interest of a subject with particles of a substance of interest by precipitation. Example methods include administering a solution to a subject, the solution including the substance of interest and a pharmaceutically acceptable solvent. The substance of interest must be soluble in a pharmaceutically acceptable, water-miscible solvent but insoluble in tissue fluids of the target tissue of interest; and the pharmaceutically acceptable solvent must be freely miscible with the tissue fluids of the target tissue of interest. According to example embodiments, the solution is administered in a volume of the pharmaceutically acceptable solvent that will be diluted by tissue fluids in the target tissue of interest following administration at a rate that will result in precipitation of an effective amount of particles of the substance of interest in a range of sizes that will accomplish a purpose for which the substance is administered. Examples of the present methods include administering the solution to tissue of an animal, such that the substance of interest in the solution precipitates and provides an effective amount of insoluble particles of the substance of interest to the tissue. Also provided are kits that include the solution or components thereof; and methods of making such solutions.
PURPOSE: A manufacturing method of functional tea is provided with antioxidant vitality using okra seeds. CONSTITUTION: After roasting okra(Abelmoschus esculentus (L.) Moench) seeds for 8-15 minutes under a temperature of about 150-230 deg. C, dry the okra seeds using a hot-air drying or freeze-drying process. Extract pulverized powder of dried okra seeds using methanol. Extract the okra seeds for 22-26 hours under 20-40 deg. C condition in 80% of methanol. The okra seed extract has 2.5-3.0 mg/g of free living amino acid contents based on okra seed pulverized powder. The Okra seed extract contains 12-13mg/g of polyphenol compounds based on the okra seed pulverized powder. Pack the pulverized powder in a granular package or a tea bag.
Coronaviruses belong to the genus of coronavirus of the family coronaviruses. The viruses of the coronavirus genus are positive-sense single-stranded RNA viruses with envelopes, which are approximately 80-160 nm in diameter. Their genetic material is the largest among all RNA viruses and can infect both humans and animals. Coronaviruses can cause respiratory, intestinal, hepatic, and nervous system diseases of different severities. A total of 7 coronaviruses have been found, in which HCoV-229E, HCoV-OC43, HCoV-NL63 and HCoV-HKU1 mainly lead to mild and self-limiting upper respiratory tract infections in infected humans, such as common cold; two new types of β-coronaviruses have emerged in the past 12 years, namely severe acute respiratory syndrome (SARS-CoV) and Middle East respiratory syndrome (MERS-CoV), and these two viruses can cause severe human diseases.

This is a Phase 1, randomized, double-blinded, placebo controlled, dose escalation study of FB2001 in healthy adult volunteers.The study aims to evaluate the safety, tolerability and pharmacokinetic profile of FB2001 administered by aerosol inhalation after single and multiple ascending doses.Approximately 32 participants will be sequentially enrolled into either 1 of 2 SAD cohorts (n=8 per cohort), or 1 of 2 MAD cohorts (n= 8 per cohort). An adaptive dose escalation schedule will be employed for both SAD and MAD parts of the study.
1. Technical Result Increase in efficiency of treatment of hematological disorders and widening of assortment of medicinal means. 2. Essence The novel oligopeptide with modulating activity of thrombopoietin receptor, obtained by recombinant way and comprising 15-18 amino acids. A pharmaceutical composition made on said oligopeptide is used for diagnostics and treatment of hematological disorders, in particular at thrombocytopenia. 3. Field of Application Medicine.
A method for treating arterial and venous thromboses comprises the medicamentous therapy with anticoagulant. The content of the total cholesterol, triglycerides, LDL VLDL in blood serum is measured prior to the treatment, in the course of the treatment, and after termination of anticoagulant therapy. The further therapy depends on the concentration of the substances stated above at the end of the treatment. When the level of total cholesterol and LDL is increased and triglyceride level is normal, statins are provided. When the level of total cholesterol, LDL, VLDL, and triglycerides is increased, the combination of statins and fibrates is provided. When the level of total cholesterol is normal, the level of LDL and triglycerides is increased, statins and/or fibrates are provided. In case of largely increased level of total cholesterol, LDL, VLDL and increased level of triglycerides, the combination of statins and fibrates is provided with extracorporeal hemocorrection (plasmapheresis).
A sensing system includes laser diodes with Bragg reflectors generating light having an initial light intensity and one or more near-infrared optical wavelengths. The laser diodes are modulated with a pulsed output with 0.5 to 2 nanosecond pulse duration. A beam splitter receives light from the laser diodes, splits the light into a received sample arm light directed to an object and a received reference arm light. A detection system includes a second lens and spectral filters in front of a photodiode array. The photodiode array is coupled to CMOS transistors and receives at least a portion of the received reference arm light and generates a reference detector signal. The detection system is synchronized with the laser diodes. A time-of-flight measurement is based on a comparison of the sample detector signal and the reference detector signal and measures a temporal distribution of photons in the received reflected sample arm light.
FMT capsules fecal capsules on two consecutive days (total of 30 capsules) within a week prior to first vedolizumab infusion. Patients who will be allocated to this treatment arm will be matched to donors according to their CMV status (past exposure - CMV positive donors will be used for CMV positive patients, and CMV negative donors will be used for CMV negative patients).
Participants receive affect-based goals for the first 8-weeks, then cross-over to receive intensity-based goals for the second 8-weeks. No enhancements are added to the standard mHealth intervention.
The invention belongs to the field of microorganism drugs and relates to a bacterial strain for producing herbimycin and an application of the bacterial strain. The bacterial strain is identified as Streptomyces hygroscopicus through analysis of a morphological characteristic, a culture characteristic, physiological and biochemical characteristics and a 16SrDNA gene. The bacterial strain is registered with the collection number of CGMCC (China General Microbiological Culture Collection Center) No.8544 in CGMCC on December 6, 2013. After being extracted by using an organic solvent and analyzed according to the detection of an ultraviolet absorption spectrum, an infrared absorption spectrum, a nuclear magnetic resonance spectrum and a mass spectrum, an active component in a supernatant liquid generated by the bacterial fermentation is proved to be Herbimycin A belonging to benzoquinone ansamycin, being up to the fermentation level of over 1500mu g/mL and being capable of realizing industrialization, convenient to extract, single in component and good in product quality. The Herbimycin A has important biological activity, broad-spectrum herbicidal activity and weak antibacterial and antifungal activity, and can be used as an anti-rejection drug for organ transplantation. In addition, the Herbimycin A has an inhibiting effect on various tumor cells.
Hypersensitivy pneumonitis (HP) are chronic respiratory diseases due to frequent exposure to high quantities of allergens (molds, bacteria, mycobacteria, avian proteins). In case of domestic HP, patients are exposed at home to molds due to flooding or poor ventilation.

The diagnosis of domestic HP includes detection of IgG towards molds. A prior study in 2005 allowed the determination of frequent allergenic molds isolated in homes in Bourgogne Franche Comte (study on 110 dwellings). However, no real cohort of proven cases versus controls is available. So, we are lacking validated thresholds. The HOME HP study is a prospective study that will include several centers of pneumology on France territory. The fungal contamination of dwellings occupied by patients suffering of interstitial disease (DIP), including suspicion of domestic HP, will be analyzed. The most frequently isolated molds will be then produced as antigens and will be tested in order to assess the sensitization of the included patients. The data of imagery, BALF cytology will allow to determine if patients are diagnosed with domestic HP or not. We will then obtain 2 groups of patients 1-proven domestic HP and 2-non domestic HP . Comparing the number of immunization arcs between the 2 groups will then be possible to validate appropriate thresholds for the serodiagnosis of domestic HP.

Domestic HP are rare diseases, so a high number of inclusions will be needed to obatin in 2 years about 25-30 proven cases. The HOME HP study is important to improve the serodiagnosis of domestic HP.
A multi-stage oral drug controlled-release system is disclosed, as well as a preparation for maintaining the drug blood concentration at a desired level for a prolonged time. The system operates by releasing the drug at a constant rate through stepwise control of drug release following administration of the preparation. More specifically, the multi-stage oral drug controlled-release system involves the stepwise release of drug-containing granules from an inner matrix, which is surrounded by a coating or release-modifying layer. The granules contain an active drug and a carrier material in size of 0.1~1 mm. The carrier material is hydrophobic when the drug has a water-solubility of 1 mg/ml or more, and is hydrophilic when the drug has a water-solubility of less than 1 mg/ml. The inner matrix, in which the drug-containing granules are embedded, is formed from swelling and erodible polymer(s) and swelling-regulating material(s). The release-modifying layer is composed of a hydrophobic release-modifying polymer, a hydrophilic release-modifying polymer, pH-dependent release-modifying polymer or mixtures thereof.
FIELD: medicine. SUBSTANCE: they use antiseptics in combination with irradiation by pulsed ultra-violet rays of not more than 2·10 -3 s pulse duration, with power density of not less than 10 kW/m 2  in zone of treatment and total energetic doze of not less than 10 2 J/m 2  . The ultraviolet pulse is formed by pulse gas discharge lamp during discharge of an accumulating capacitor in the moment, defined by high-voltage firing gas discharge pulse of a firing pulse generator, that is inductively coupled with the discharge circuit for instance by means of a pulse transformer. Parameters of the discharge circuit are interrelated by a ratio, that ensures optimum regime of discharge in the inert gas, that fills the lamp. EFFECT: method and apparatus are useful in surgery. 3 cl, 3 dwg